Skip to main content

SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody)

Rheumatology International volume 26, pages 771–772 (2006)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46(10):2673–2677

    PubMed  Article  Google Scholar 

  2. Weide H, Pandorf K (2003) Successful long term treatment of SLE with Rituximab maintainance therapy. Lupus 12(10):779–782

    Article  Google Scholar 

  3. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ (2000) Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 59(2):120–124

    PubMed  Article  CAS  Google Scholar 

  4. D’Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J, Khamashta MA, Hughes GR (2004) Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of anti-phospholipid antibodies. J Rheumatol 31(2):280–285

    PubMed  Google Scholar 

  5. Tellez-Zenteno JF, Remes-Troche JM, Negrete-Pulido RO, Davila-Maldonao L (2001) Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases. Lupus 10(12):851–856

    PubMed  Article  CAS  Google Scholar 

  6. Kimura KY, Seino Y, Hirayama Y, Aramaki T, Yamaguchi H, Amano H, Takano T (2002) Systemic lupus erythematosus related transverse myelitis presenting with longitudinal involvement of the spinal cord. Intern Med 41(2):156–160

    PubMed  Article  Google Scholar 

  7. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B (2002) Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 116(2):465–467

    PubMed  Google Scholar 

  8. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50(8):2580–2589

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Rheumatology, Musgrave Park Hospital, Belfast, UK

    D. J. Armstrong, M. T. McCarron & G. D. Wright

Authors
  1. D. J. Armstrong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. T. McCarron
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. D. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. J. Armstrong.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Armstrong, D.J., McCarron, M.T. & Wright, G.D. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int 26, 771–772 (2006). https://doi.org/10.1007/s00296-005-0068-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-005-0068-1

Keywords

  • Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus Patient
  • Myelitis
  • Oral Prednisolone
  • Intravenous Cyclophosphamide